ArticleMolecular and clinical oncology2023
Pertuzumab as second‑ or later‑line therapy for human epidermal growth factor receptor 2‑positive metastatic breast cancer: A clinical experience.
Ewelina Biskup et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.